Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

BACKGROUND: PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each developed with a different ICI. We set to test if next generation...

Descripción completa

Detalles Bibliográficos
Autores principales: Conroy, Jeffrey M., Pabla, Sarabjot, Nesline, Mary K., Glenn, Sean T., Papanicolau-Sengos, Antonios, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Wang, Yirong, Lenzo, Felicia L., Bshara, Wiam, Khalil, Maya, Dy, Grace K., Madden, Katherine G., Shirai, Keisuke, Dragnev, Konstantin, Tafe, Laura J., Zhu, Jason, Labriola, Matthew, Marin, Daniele, McCall, Shannon J., Clarke, Jeffrey, George, Daniel J., Zhang, Tian, Zibelman, Matthew, Ghatalia, Pooja, Araujo-Fernandez, Isabel, de la Cruz-Merino, Luis, Singavi, Arun, George, Ben, MacKinnon, Alexander C., Thompson, Jonathan, Singh, Rajbir, Jacob, Robin, Kasuganti, Deepa, Shah, Neel, Day, Roger, Galluzzi, Lorenzo, Gardner, Mark, Morrison, Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346512/
https://www.ncbi.nlm.nih.gov/pubmed/30678715
http://dx.doi.org/10.1186/s40425-018-0489-5

Ejemplares similares

Ejemplares similares